Anti-IGSF1 antibody and use thereof
A novel antibody that specifically binds to IGSF1 and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. Specifically, an antibody that binds to the C-terminus of IGSF1. Therefore, the anti-IGSF1 antibody may be utilized as an anticancer agent for effectively treating cancer in which IGSF1 is overexpressed.
1 . An antibody specific for IGSF1 or a fragment thereof, comprising
a heavy chain variable region comprising H-CDR1 of SEQ ID NO: 1, H-CDR2 of SEQ ID NO: 2 and H-CDR3 of SEQ ID NO: 3; and
a light chain variable region comprising L-CDR1 of SEQ ID NO: 4, L-CDR2 of SEQ ID NO: 5 and L-CDR3 of SEQ ID NO: 6.
2 . The antibody specific for IGSF1 or fragment thereof according to claim 1 , wherein
the heavy chain variable region has the amino acid sequence of SEQ ID NO: 7; and
the light chain variable region has the amino acid sequence of SEQ ID NO: 8.
3 . A polynucleotide encoding a heavy chain variable region comprising H-CDR1 of SEQ ID NO: 1, H-CDR2 of SEQ ID NO: 2 and H-CDR3 of SEQ ID NO: 3.
4 . A polynucleotide encoding a light chain variable region comprising L-CDR1 of SEQ ID NO: 4, L-CDR2 of SEQ ID NO: 5 and L-CDR3 of SEQ ID NO: 6.
5 . An expression vector comprising the polynucleotide according to claim 3 .
6 . An expression vector comprising the polynucleotide according to claim 4 .
7 . A transformed cell into which the expression vector according to claim 5 is introduced.
8 . A transformed cell into which the expression vector according to claim 6 is introduced.
9 . A method of producing an antibody specific for IGSF1 or a fragment thereof, comprising:
i) culturing the transformed cell according to claim 7 ; and
ii) recovering the antibody specific for IGSF1 or the fragment thereof.
10 . A method of producing an antibody specific for IGSF1 or a fragment thereof, comprising:
i) culturing the transformed cell according to claim 8 ; and
ii) recovering the antibody specific for IGSF1 or the fragment thereof.
11 . A method for treating cancer, the method comprising administering to a subject the antibody specific for IGSF1 or fragment thereof according to claim 1 .
12 . The method according to claim 11 , wherein the cancer is one in which IGSF1 is overexpressed.
13 . The method according to claim 11 , wherein the cancer is any one selected from the group consisting of gastric cancer, liver cancer, lung cancer, non-small cell lung cancer, colorectal cancer, bladder cancer, bone cancer, blood cancer, breast cancer, melanoma, thyroid cancer, parathyroid cancer, bone marrow cancer, rectal cancer, throat cancer, laryngeal cancer, esophageal cancer, pancreatic cancer, tongue cancer, skin cancer, brain tumor, uterine cancer, head or neck cancer, gallbladder cancer, oral cancer, perianal cancer, colon cancer, and central nervous system tumor.
14 . A pharmaceutical composition comprising the antibody specific for IGSF1 or fragment thereof according to claim 1 as an active ingredient.